FL118, acting as a ‘molecular glue degrader’, binds to, dephosphorylates and degrades the oncoprotein DDX5 (p68) to control c‐Myc, survivin and mutant Kras against colorectal and pancreatic cancer with high efficacy
Abstract
Pancreatic ductal adenocarcinoma (PDAC), a difficult‐to‐treat cancer, is expected to become the second‐largest cause of cancer‐related deaths by 2030, while colorectal cancer (CRC) is the third most common cancer and the third leading cause of cancer deaths. Currently, there is no effective treatment for PDAC patients. The development of novel agents to effectively treat these cancers remains an unmet clinical need. FL118, a novel anticancer small molecule, exhibits high efficacy against cancers; however, the direct biochemical target of FL118 is unknown.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- May 01, 2022
- Source ID
- 10.1002/ctm2.881
Entities
People
- Christos Fountzilas
- Fengzhi Li
- Ieman A. M. Aljahdali
- Jianqun Liao
- Patrick M. Boland
- Sreevidya Santha
- Wenjie Wu
- Xiang Ling
Organizations
- National Cancer Institute
- National Institutes of Health
- Pancreatic Cancer Action Network
- Roswell Park Comprehensive Cancer Center
- United States Department of Defense